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MicroRNAs (miRNAs) are short non-coding RNAs that have key functions in a wide array of critical cell processes, including
haematopoiesis by regulating the expression of multiple genes. Aberrant miRNA expression has been described in acute myeloid
leukaemia suggesting a role in leukaemogenesis. In this review we summarise the current knowledge.
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Acute myeloid leukaemia (AML) arises from myeloid progenitor
cells that are arrested at early stages of differentiation. It is a
cytogenetically heterogeneous disorder with acquired recurrent
chromosomal alterations detected in about 55% of adult patients,
such as translocations (i.e. t(15;17); t(8;21); t(9;11)), inversions (i.e.
inv(16)), deletions (i.e. del(7q)), trisomies (i.e. þ8) and mono-
somies (i.e.  5/ 7) (reviewed by Mro ´zek et al, 2004). Importantly,
AML patients could be stratified according to the detected
cytogenetic abnormalities in high-, intermediate- and low-risk
cytogenetic groups (Mro ´zek et al, 2004). In the remaining 45% of
cases of cytogenetically normal AML (CN-AML), a number of
novel molecular abnormalities have been described, such as the
internal tandem duplication (ITD) in the juxtamembrane domain
or mutation in the second tyrosine kinase domain (TKD) of FMS-
like tyrosine kinase 3 (FLT3) gene, mutations in the nucleo-
phosmin (NPM1) gene, CCAAT/enhancer binding protein-a
(CEBPA) gene and in the Wilms’ tumour gene and partial tandem
duplication (PTD) of the mixed-lineage leukaemia (MLL) gene
(reviewed by Mro ´zek et al, 2007). In addition to mutations,
overexpression of ERG (v-ets erythroblastosis virus E26 oncogene
homologue) and BAALC (brain and acute leukaemia, cytoplasmic)
genes has been found in CN-AML (Tanner et al, 2001; Baldus et al,
2004). Like cytogenetics, molecular abnormalities in CN-AML not
only have improved the classification of this now heterogeneous
group of AMLs, but also have prognostic implications. For
example, NPM1 mutations predict favourable outcome in young
CN-AML in the absence of FLT3-ITD (reviewed by Mro ´zek et al,
2007). The presence of CEBPA mutations identifies a group of
patients with a better prognosis within the young high-risk
CN-AML group (patients with FLT3-ITD and/or wild-type (wt) NPM1)
(Marcucci et al, 2008b). Otherwise, CN-AML patients with FLT3-
ITD have a significantly inferior outcome compared to patients
with FLT3-wt (reviewed by Mro ´zek et al, 2007). The level of
FLT3-ITD mutant allele was also correlated with outcome,
whereas the prognosis impact of FLT3-TKD is controversial.
MLL-PTD has been associated with shorter complete remission
duration or worse event-free survival (EFS) without effect on
overall survival (reviewed by Mro ´zek et al, 2007). Many of these
prognostic studies are difficult to interpret because of the co-
existence of one or two mutations which have to be taken in
consideration because of their probable interactions and influence
on prognosis. Additional limitations arise from the low number of
patients and treatment differences (reviewed by Gaidzik and
Do ¨hner, 2008).
Despite great progress, AML biology remained poorly under-
stood. Over the past years, complementary DNA (cDNA) micro-
arrays have been used to interrogate whole gene expression in
AML samples. Indeed, several groups have reported distinctive
signatures associated with particular cytogenetic and molecular
groups of AML (Bullinger et al, 2004; Ross et al, 2004; Valk et al,
2004; Radmacher et al, 2006). Using unsupervised analyses, we
identified novel subgroups of AMLs based on gene expression
profiling (GEP) obtained using Affymetrix microarrays. Moreover
GEP allowed to further classify previously defined cytogenetic
subgroups. For example, GEP uncovered substantial heterogeneity
in core binding factor (CBF) AMLs suggesting alternative
mutations or deregulated pathways involved in transformation
(Bullinger et al, 2007). In some cases, the GEP signatures were able
to predict outcome (Bullinger et al, 2004; Ross et al, 2004; Valk
et al, 2004). More importantly, a cDNA microarray study identified
a gene expression signature that separated CN-AML into two
prognostically relevant subgroups (Bullinger et al, 2004). The
prognostic value of this signature was validated in a different set of
CN-AML patients using a different microarray platform (Radma-
cher et al, 2006). These studies confirmed the possible applicability
of GEP for outcome prediction in CN-AML. Despite this progress,
focusing on known genes will likely not suffice to uncover the
molecular puzzle of AML. The integration of a whole genome
approach including non-coding RNAs may lead to an improved
understanding of AML biology.
MicroRNAs (miRNAs) are non-coding RNAs of 19–25 nucleo-
tides in length that regulate gene expression by repressing
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are involved in critical biological processes, including develop-
ment, cell differentiation, apoptosis, proliferation and haemato-
poiesis (Chen et al, 2004; Poy et al, 2004; Xu et al, 2004; Cheng
et al, 2005; Karp and Ambros, 2005). Recent data indicate that
miRNAs are deregulated in diseases, such as diabetes, heart disease
and cancer (Calin et al, 2002; Poy et al, 2004; van Rooij et al, 2006).
The first study connecting miRNAs and leukaemia reported
frequent down-regulation of the miRNA cluster; miR-15a/miR-16-1
in chronic lymphocytic leukaemia (CLL) (Calin et al, 2002). This
cluster is localised at chromosome 13q14.3, a genomic region,
which is deleted in about 65% of CLL patients. Further work
showed that miR-15a/miR-16-1 cluster targets the anti-apoptotic
BCL-2 (Cimmino et al, 2005). Thereby, this study provides with an
alternative explanation for the BCL-2 up-regulation observed in
CLL. Following earlier reports, two large miRNA profiling studies
confirmed the widespread deregulation of miRNAs in cancer (Lu
et al, 2005; Volinia et al, 2006). But how miRNAs contribute to
oncogenesis? Further research established that miRNAs can behave
as tumour suppressor genes or oncogenes (Calin and Croce, 2006;
Garzon et al, 2006). An miRNA, which is down-regulated and
targets an oncogene, acts as a tumour suppressor gene. For
example, let-7a, which is down-regulated in lung adenocarcinoma,
targets the highly expressed oncogene K-RAS (Johnson et al, 2005).
In contrast, an miRNA which is over-expressed and targets a
tumour suppressor gene acts as an oncogene (Calin and Croce,
2006; Garzon et al, 2006). For example, high expression of miR-155
and its host gene, the non-coding RNA B-cell integration cluster
(BIC) has been reported in different human B-cell neoplasms
suggesting a role for miR-155 in B-cell lymphomagenesis (Eis et al,
2005). This hypothesis was later confirmed by Costinean et al
(2006) who reported an miR-155 transgenic mouse developing
a polyclonal pre-leukaemic pre-B-cell proliferation evident in
the spleen and bone marrow (BM) followed by a full-blown
malignancy.
Over the past 3 years, several groups have described miRNA
signatures associated with recurrent cytogenetic abnormalities,
molecular aberrations and outcome in AML. In this review we
discuss the current miRNA profiling studies in AML and outline
future prospects and potential therapeutic applications.
miRNA EXPRESSION IN AML BLASTS, STEM CELLS
AND COMMITTED PROGENITORS
Four recent large-scale studies have reported miRNA expression in
primary AML blasts and CD34þ selected cells (Garzon et al,
2008a; Jongen-Lavrencic et al, 2008) or BM samples (Dixon-McIver
et al, 2008; Li et al, 2008) from healthy donors. Garzon et al
(2008a) identified 26 down-regulated miRNAs and none up-
regulated miRNAs in 122 newly diagnosed AML samples compared
with BM CD34þ cells from 10 normal donors using a custom
microarray platform. This is consistent with the miRNA profiling
results obtained from 334 tumours, including leukaemias, and
normal tissues using a bead-based flow cytometric miRNA
platform (Lu et al, 2005). Lu et al (2005) found in general a lower
expression of miRNAs in tumours compared with normal tissues.
They hypothesised that global miRNA expression might reflect the
state of cellular differentiation. Indeed, they observed in haema-
topoietic progenitor cells undergoing erythroid differentiation an
increase in miRNA expression at a later stage of differentiation (Lu
et al, 2005).
A second AML study analysed 215 newly diagnosed leukaemic
patients and CD34þ cells from four healthy subjects using a
multiplexing real-time quantitative polymerase chain reaction
(qRT-PCR) method (Jongen-Lavrencic et al, 2008). Only 11
miRNAs (5 up- and 6 down-regulated) were found differentially
expressed in normal CD34þ specimens with respect to the
leukaemias. Among them, miR-21 was found up-regulated in AML
samples compared with CD34þ cells.
The two other studies compared miRNA expression in AML
samples with BM from healthy donors. Dixon-McIver et al (2008)
showed the significant deregulation of 33 miRNAs (17 up-
regulated and 16 down-regulated) in 100 leukaemia samples with
respect to two BM samples using a qRT-PCR assay. Li et al (2008)
using bead-based miRNA expression profiling assays analysed 54
AML samples and 3 normal BM samples. Normal control samples
were grouped together in a subcluster with unsupervised analysis.
Only few miRNAs were commonly (in at least two studies)
down-regulated in AML patients, such as miR-29b and miR-126.
Many factors might be involved in the disparities of the results
from these studies. First, the purity of the leukaemic cells might
influence the results. There could be differences in the blast
percentage among the studies that could impact on the profiling.
In one study, selection purity was improved by CD3/CD19
depletion after Ficoll separation of mononuclear cells. Second,
the nature of the control sample is critical and can also explain the
discrepancies. Two studies used BM CD34þ cells whereas the
other two used whole BM or mononuclear cells. Third, other
factors such as biology differences in the AMLs included in the
studies, number of control samples, processing, platform and
bioinformatics approaches (data normalisation, filtering and
clustering) may influence the results. Further studies will be
needed using highly pure populations, including CD34þ selected
leukaemic cells, to assess miRNA changes with respect to CD34þ
normal cells.
miRNA SIGNATURES ASSOCIATED WITH
CYTOGENETIC AND MOLECULAR ALTERATIONS IN
AML
Garzon et al (2008a)analysed the miRNA expression in a cohort of
122 newly diagnosed primary AML samples with intermediate and
poor prognosis using a custom miRNA platform. The authors
identified miRNA expression profiles closely linked to 11q23
translocations, trisomy 8 and FLT3-ITD (Tables 1 and 2). Among
the miRNAs down-regulated in balanced 11q23 translocation
patients, many are tumour suppressor miRNAs that target critical
oncogenes, i.e., miR-34b (CDK4 and CCNE2), miR-15a (BCL-2), the
let-7 family (RAS), the miR-29 family (MCL-1 and TCL-1) and miR-
372 (LATS2). Interestingly, miR-155 was found up-regulated in
AML patients with high white count and FLT3-ITD mutations.
This miRNA has been recently described to block ‘in vitro’ human
myeloid colony formation, halt megakaryopoiesis (Romania et al,
2008) and induce a myeloproliferative disease in mice (O’Connell
et al, 2008). A second study by Jongen-Lavrencic et al (2008)
reported miRNA profiles using a qRT-PCR platform in 215 AML
patients that include among others good risk karyotypes such as
t(15;17), t(8;21) and inv(16). Using a combination of unsupervised
and supervised analyses the authors identified distinctive miRNA
expression profiles associated with known AML cytogenetic
subtypes (Tables 1 and 2). Among them, the tumour suppressor
miRNAs let-7b and let-7c (known to target the oncogenes RAS)
were found down-regulated in CBF leukaemias (Johnson et al,
2005). None of these deregulated miRNAs was localised in the re-
arranged chromosomal regions. Finally, the authors determined
the minimal set of miRNAs and mRNAs (by performing GEP on
the same AML cohort) that could predict a particular genetic
subtype of AML. The mRNA-GEP class predictor was accurate in
predicting AML with t(15;17), t(8;21) or inv(16) as well as CN-AML
samples with NPM1, CEBPA mutations and FLT3-ITD. Another
study using a qRT-PCR assay reported miRNA signatures that
correlate with the most frequent cytogenetic alterations (t(15;17),
t(8;21), inv(16), 11q23 translocations) in 100 AML samples. In
particular, acute promyelocytic leukaemias bearing a t(15;17) had a
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located on chromosome 14q32 which is not implicated in the
translocation (Table 1; Dixon-McIver et al, 2008). More recently,
the study of Li et al using another genome-wide bead-based
miRNA expression platform analysed 52 AML samples with
common translocations including t(8;21), inv(16), t(15;17) and
MLL rearrangements (Table 1).
We reported in Table 1 the most significant miRNAs deregu-
lated in association with the different cytogenetic subtypes in these
four studies. In particular, we showed common miRNAs found
up- or down-regulated by at least two studies in each subtypes
(Table 1).
Li et al determined the minimal number of miRNAs that can
accurately discriminate AML subtypes. Two (miR-126 and miR-126*),
three (miR-224, miR-368 and miR-382) and seven miRNAs
(from the polycistronic miR17-92 cluster) are sufficient to predict
CBF AML, t(15;17) and MLL AML respectively, resulting in a
diagnosis accuracy better than 94% (Table 1). Some of these
differentially expressed miRNAs were also identified in the class
predictor reported by Jongen-Lavrencic including miR-126* in
CBF leukaemias or miR-382 in t(15;17) AML.
Garzon et al (2008b)focused on CN-AML with NPM1 mutation
which is the most common genetic alteration in CN-AML. They
profiled 85 de novo AML patients (55 with NPM1 mutation and
30 with NPM1 wt) and found a strong miRNA signature that distin-
guishes CN-AML with NPM1 mutation from NPM1 wt (Table 2).
The up-regulation of miR-10a and miR-10b in NPM1-mutated
AML clearly differentiate the two different forms. These results
were confirmed by Jongen-Lavrencic et al and in a recent study of
189 older CN-AML (Becker et al, 2009). Among the other miRNAs
up-regulated, three families of tumour suppressor miRNAs were
involved: miR-15a/16-1, several let-7 and miR-29 members whereas
miR-204 and miR-128a were down-regulated (Garzon et al, 2008b).
Concerning CEBPA mutations, Marcucci et al (2008b) reported an
Table 1 Most significant miRNAs and common miRNAs (in red) deregulated following cytogenetic alterations in AML
Chromosomal
alteration miRNAs
t(15;17) m miR-193b/379/382/485-5p/134/376a/299-5p/452/127/224/432/370/100/323/125b/154/424/181a,b,d
k miR-196a,b/151/10b/let-7c (Jongen-Lavrencic et al, 2008)
m miR-127/154/154*/299/323/368/370 – k miR-17-3p/185/187/194/200a,b,c/330/339 (Dixon-McIver et al, 2008)
m miR-181a,b,c,d/224/368/382/424/100/125b – k miR-126/126*/150/17-5p/20a/422b/10a/124a (Li et al, 2008)
inv(16) m miR-424/199b/365/335/511 – k miR-10a,b/196a,b/127/192/let-7b,c (Jongen-Lavrencic et al, 2008)
m miR-99a/100/224 (Dixon-McIver et al, 2008)
t(8;21) m miR-126* – k let-7b,c/miR-148a/125b/99a/133a,b/9/10a,b/196a,b/133a (Jongen-Lavrencic et al, 2008)
m miR-146a – k miR-133a (Dixon-McIver et al, 2008)
inv(16)+t(8;21) m miR-126/126*/130a – k miR-196b/17-3p,5p/18a/19a,b/20a/92 (Li et al, 2008) -
11q23 balanced
translocations
m miR-326/219/194/301/324/339/99b/328 – k miR-34b/15a/29a/29c/372/30a/29b/30e/196a/ let7f/102/331/299/193 (Garzon et al, 2008a)
m miR-9/429 – k miR-213/146a (Jongen-Lavrencic et al, 2008)
m miR-196b/17-3p,5p/18a/19a,b/20a/92/93/10a,b/124a – k miR-126/126*/130a/146a/181a,b,c,d/224/368/382/424 (Li et al, 2008)
Trisomy 8 m miR-124a/30d/337/184/302b/105/let7d/153/215/1/194 (Garzon et al, 2008a)
5q-/7q- m miR-125a/let-7e/130a/203 – k miR-223/9/148a/182/99a/10b (Jongen-Lavrencic et al, 2008)
Table 2 Most significant and common miRNAs (in red) deregulated following molecular alterations in cytogenetically normal AML
Molecular
alteration miRNAs
FLT3-ITD m miR-155/10a,b (Garzon et al, 2008a)
m miR-155/10b/511/135a – k miR-143/338/30a-3p/182/145/130a/214/203 (Jongen-Lavrencic et al, 2008)
NPM1 mutation m miR-10a,b/100/let-7a-3/21/16a,b/29a,b,c/16-1/17-92 cluster – k miR-192/299/128a/198/429/326/204/127/299-5p/193b (Garzon et al, 2008b)
m miR-10a,b/196a,b/135a/let-7b – k miR-320/335/130a/126*/424/365/450/127/299-5p/193b (Jongen-Lavrencic et al, 2008)
CEBPA mutation m miR-335/181a – k miR-196a,b/149/9/21/130b/let-7b/99b/148a (Jongen-Lavrencic et al, 2008)
m miR-128/181a,b,c,d/192/219-1-3p/224/335/340 – kmiR-34a/194 (Marcucci et al, 2008b)
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mutation in CN-AML patients. Interestingly, miR-181a and
miR-181b were up-regulated in CEBPA-mutated cases. These
results are consistent with a CEBPA mutation miRNA signature
reported by Jongen-Lavrencic.
PROGNOSTIC ROLE OF MiRNAs IN AML
Few studies have correlated miRNA expression changes with
prognosis in AML. Garzon et al (2008a) first reported that in a
relatively older AML cohort of patients (median age 59) with
intermediate- and poor-risk cytogenetics, patients with high
expression of miR-199a and miR-191 had a significant shorter
overall survival and EFS. These results were validated in a second
cohort of 60 AML patients with similar characteristics using a
different technology; qRT-PCR. These two miRNAs (miR-191 and
miR-199a) predicted outcome independent from other variables,
including age and cytogenetics. Marcucci et al (2008a) recently
showed an miRNA signature that correlated with EFS in young
CN-AML patients (o60 years) with high-risk molecular features
(defined by the detection of FLT3-ITD and/or an NPM1 wt). This
subgroup of AML represents more or less a third of young
AML patients. The prognostic signature included miR-181a and
miR-181b which were inversely correlated with risk of event and
miR-124, miR-128-1, miR-194, miR-219-5p, miR-220a, miR-320
which were positively associated with the risk of event. This
prognostic signature was independent from other factors. Further-
more, using mRNA gene-chip microarray analysis, the authors
showed an inverse correlation between the expression of miR-181
and predicted target genes. Many of these genes encode for
proteins involved in pathways of innate immunity mediated
by Toll-like receptors (TLR2, TLR4, TLR8) and interleukin-1b
(NOD-like receptors CARD8, 12, 15 and CASP1). Activation
of Toll-like receptors induces production of inflammatory
cytokines through nuclear factor kB and interleukin-1b promotes
the survival and the proliferation of AML blasts. No miRNA
was found to be associated with outcome in low-risk group
(NPM1 mutation alone) (Marcucci et al, 2008a). Both prognostic
signatures need to be confirmed in large prospective studies before
clinical applications. The different prognostic miRNA signatures
between the two studies can be explained by two main factors.
First, the median age between the two studies was different; 60.3
years (range 18–86) vs 45 years (range 19–45). This is critical
because FLT3-ITD and NPM1 prognostic implications are age
dependent. FLT3-ITD has been shown to have a negative
prognostic impact only in young AML patients (reviewed by
Mro ´zek et al, 2007), whereas it is not prognostic in the elderly
(Stirewalt et al, 2001; Garzon et al, 2008a). NPM1 mutation seems
to be an independent prognostic factor in young and older AML
patients but only in the absence of FLT3-ITD in the young patients
cohort (reviewed by Gaidzik and Do ¨hner, 2008; Becker et al, 2009).
Second, the cytogenetic/molecular subgroups studied were differ-
ent. Garzon et al (2008a) studied intermediate- and poor-risk
cytogenetic groups, whereas Marcucci et al (2008a) focused on
high-risk CN-AML.
miRNAs AND HOX GENES
HOX genes are transcription factors which are important in the
regulation of early stages of haematopoiesis, including self-renewal
of haematopoietic stem cells (Sauvageau et al, 1995). Five miRNAs
are embedded in the HOX genes cluster – miR-196b in HOXA (at
chromosome 7p15), miR-10a and 196a-1 in HOXB (at chromosome
17q21), miR-196a-2 in HOXC (at 12q13) and miR-10b in HOXD
(at 2q31) clusters. A distinctive correlation between the miR-10a,
miR-10b and miR-196-1 and the HOXA/HOXB gene expression was
first reported in 30 AML patients suggesting a common regulatory
mechanism (Debernardi et al, 2007). Kuchenbauer et al (2008)
recently showed an up-regulation of all the miRNAs located in the
HOX cluster in a murine leukaemia model (engineered by over-
expression of NUP98/HOXD13 fusion gene with the oncogenic
collaborator MEIS1).
NPM1, miRNAs and HOX genes
Interestingly, miR-10a, 10b and miR-196b have recently been
linked to molecular or chromosomal alterations in subtypes of
AML, in particular CN-AML with mutated NPM1. Garzon et al
(2008b) identified a statistically significant up-regulation miR-10a,
miR-10b in CN-AML with NPM1 mutation. The over-expression
was correlated with high expression level of HOX genes (mainly
HOXB genes) (Garzon et al, 2008b). These results were validated by
other groups (Debernardi et al, 2007; Jongen-Lavrencic et al, 2008;
Becker et al, 2009). Whether these miRNAs are merely bystanders
or involved in leukaemogenesis is still under investigation. Among
the miRNAs down-regulated in NPM1-mutated AML, miR-204
directly targets HOXA10 and MEIS1 (Garzon et al, 2008b). Over-
expression of HOXA10 in murine haematopoietic stem cells was
reported to perturb myeloid differentiation and to lead to AML
(Thorsteinsdottir et al, 1997). Similar outcome was shown by over-
expressing HOXA9 and MEIS1 in mice (Kroon et al, 1998). The
data suggest that miRNAs may be responsible in part of the HOX
up-regulation observed in NPM1-mutated AML.
MLL- and HOX-embedded miRNAs
Popovic et al (2009) reported that miR-196b is over-expressed
specifically in AML with MLL rearrangement. The MLL gene
(located in 11q23) is commonly involved in chromosomal
translocations (with more than 60 different fusion partners
reported) responsible of AML. Leukaemias related with MLL are
in most of the cases characterised by an over-expression of a
subset of HOX genes including HOXA9 (Rozovskaia et al, 2001).
MLL binds to specific clusters of CpG islands of HOXA9, adjacent
to miR-196b, and maintains its expression by protecting these
clusters from DNA methylation (Erfurth et al, 2008). Recently,
Popovic et al (2009) showed that MLL regulates miR-196b
expression similarly to the surrounding HOX genes. Moreover,
MLL fusion proteins cause up-regulation of miR-196b in primary
BM cells (Popovic et al, 2009). MiR-196b over-expression seems to
increase proliferation, survival and partially block the differentia-
tion of normal BM haematopoietic progenitor cells suggesting
importance of miR-196b in MLL leukaemias. It is noteworthy that
the MLL fusion proteins have also been shown to interact directly
with Drosha, the nuclear RNase III enzyme crucial in miRNA
biogenesis (Nakamura et al, 2007).
miRNAs AND EPIGENETICS
Recent data indicate that miRNAs are targets of aberrant
epigenetics in AML. The ETO/AML1 is the fusion protein resulting
from the t(8;21) translocation detected in about 15% of AML. The
in vitro expression of ETO/AML1 in haematopoietic stem cells
leads to the expansion of the myeloid progenitors and a pre-
leukaemic state. Fazi et al (2007) showed that the binding of AML1
to the pre-miR-223 promoter is responsible for miR-223 transcrip-
tion activation. The ETO/AML1 protein can bind to this site and
activate histone deacetylates and DNA methyltransferases, thereby
blocking the transcription of miR-223 by inducing histone
deacetylation and increasing DNA methylation.
Our group recently reported that over-expressing miR-29b in
AML cell lines and primary AML blasts down-regulates the
expression of DNA methyltransferases; DNMT1, DNMT3A and 3B.
MiR-29b targets directly DNMT3A and 3B and indirectly DNMT1
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DNA hypomethylation and re-expression of tumour suppressor
genes such as the cyclin-dependent kinase inhibitor p15
INK4b
and the oestrogen receptor ESR1 genes (Garzon et al, 2009).
DISCUSSION AND FUTURE DIRECTIONS
In this review, we described four recent large-scale global miRNA
profiling studies in AML. The differences among the miRNA
signatures reported by these studies can be explained mainly by
the use of various cytogenetic and molecular AML subgroups and
by the type of platform used to interrogate miRNA expressions.
The frequencies of cytogenetic/molecular abnormalities were
clearly different among the studies. For example, Garzon et al
focused on intermediate and poor prognostic cytogenetic groups
of AML, whereas Jongen-Lavrencic included good risk subgroups
such as t(8;21), inv(16) and t(15;17). Because most of the strategies
to identify distinctive miRNA signatures were based on two-way
comparisons (i.e. inv(16) vs all other AMLs), the heterogeneity of
the other AMLs will impact greatly on the analysis. This bias is less
evident when the authors focus on well-characterised cytogenetic
and molecular subgroups of AML. Common miRNAs have been
found deregulated in CN-AML cases with FLT3-ITD, NPM1 and
CEBPA mutated and in patients with t(15;17), inv(16) and t(8;21).
These results are significant because they will provide with a set of
validated miRNAs whose functions will be further investigated.
These studies may lead to a better molecular classification,
understanding of AML biology and discovery of novel targets for
treatment. In addition to improving diagnosis, miRNA signatures
may enhance current prognostic markers and help to better
stratify patients for treatment. But before any clinical applications,
miRNA profiling studies require to be extensively validated and
more standard, reliable and reproducible platforms will need to be
developed. Future miRNA expression studies should use very well
cytogenetically and molecularly characterised AML subtypes to
minimise biology heterogeneity. Generation of small RNA libraries
and next-generation deep sequencing will enable not only to
quantify the whole miRNA transcripts but also to obtain sequences
information and discover new miRNAs.
We also believe that miRNAs studies have potential relevant
therapeutic implications. Synthetic miRNAs or anti-miRNAs alone
or in association with chemotherapy could be promising in future
AML therapies. Synthetic miRNAs can be used to restore lost
tumour suppressor miRNAs expression. The other strategy (so far
more developed) is to silence oncogenic miRNAs (with ‘anta-
gomirs’ or anti-miRNA oligonucleotides or locked nucleic-acid-
modified oligonucleotides) which are over-expressed in AML
(Kru ¨tzfeldt et al, 2005). Moreover, the impact of some drugs,
such as DNA-demethylating agents, on miRNAs expression is also
another therapeutic approach to modulate miRNA expression. If
miRNA-based therapy offers new perspectives, several issues have
still to be considered such as off-target effects, chemistry
considerations and target delivery. A better comprehension of
the regulation and function of the miRNAs will be necessary to
develop future miRNA-based new drugs.
CONCLUSION
Altogether, the data suggest that miRNAs may complement and
enhance our current knowledge about AML. MicroRNA expression
profiling has been associated with cytogenetic and molecular
subtypes of AML. Functional studies suggested miRNAs may play
a role in AML pathogenesis being involved in essential pathways
for myeloid differentiation. It is now well demonstrated that
miRNAs represent a class of genes with a great potential for
diagnosis, prognosis and therapy in AML. MicroRNA-based
therapy will certainly play a role in the future of treatment of AML.
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